Evidence map›Paper›PMID 40608419›Full record

ArticleThe Journal of clinical investigation2025

Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma.

Jithma P Abeykoon, Shuhei Asada, Guangli Zhu, Yuna Hirohashi, Lisa Moreau, Divya Iyer, Sirisha Mukkavalli, Kalindi Parmar, Gabriella Zambrano, Lige Jiang and 10 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Targeting tumor transition windows.Exploration of targeted anti-tumor therapy · 2026
    Review
  7. Defective Microhomology-Mediated End-joining in SMARCB1-Deficient Tumors.bioRxiv : the preprint server for biology · 2025
    Article
  8. Disruption of Microhomology-mediated End-joining in Ewing Sarcoma.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jithma P AbeykoonDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Shuhei AsadaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Guangli ZhuDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Yuna HirohashiDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Lisa MoreauDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Divya IyerDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Sirisha MukkavalliDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Kalindi ParmarDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Gabriella ZambranoDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Lige JiangDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Dongni YiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Michelle ManskeDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Kimberly GwinDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Rebecca L KingDepartment of Pathology.
James R CerhanDepartment of Quantitative Health Sciences, and.
Xiaosheng WuDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Zhenkun LouDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Geoffrey I ShapiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Thomas WitzigDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Alan D'AndreaDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI HOUTMAN, JON C.D. · 2002 to 2021
$45.7M
NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA097274
6 · The paper itself

Abstract

Oncogene expression can cause replication stress (RS), leading to DNA double-strand breaks (DSBs) that require repair through pathways such as homologous recombination, nonhomologous end-joining, and microhomology-mediated end-joining (MMEJ). Cyclin D1 (encoded by CCND1) is a well-known oncoprotein overexpressed in cancer; however, its role in RS is unknown. Using mantle cell lymphoma (MCL) as a naturally occurring model of cyclin D1 overexpression, we examined the impact of cyclin D1 on RS and DSB repair mechanisms. Cyclin D1 overexpression elevated RS, increased DNA damage, especially during mitosis, and caused specific upregulation of MMEJ. Furthermore, cyclin D1 activated polymerase theta (POLQ) transcription by binding its promoter loci, driving POLΘ-mediated MMEJ that is essential to withstand cyclin D1-induced RS. Moreover, concurrent ATM deficiency further intensified RS, enhanced POLQ expression, and heightened reliance on MMEJ-mediated DNA damage repair. Consequently, inhibition of POLΘ in cyclin D1-overexpressed settings further exacerbated RS, causing single-strand DNA gap accumulations and chromosomal instability, ultimately leading to apoptosis, an effect amplified in ATM-deficient cells. Targeting MMEJ via POLΘ inhibition is therefore an effective strategy in the context of cyclin D1 overexpression and ATM deficiency and may provide a unique therapeutic approach for treating MCL and other malignancies characterized by similar alterations.

Indexed as

Cyclin D1DNA End-Joining RepairDNA ReplicationGene Expression Regulation, NeoplasticLymphoma, Mantle-CellNeoplasm ProteinsAtaxia Telangiectasia Mutated ProteinsCell Line, TumorDNA Breaks, Double-StrandedDNA-Directed DNA PolymeraseDNA Polymerase thetaHumansAtaxia Telangiectasia Mutated ProteinsATM protein, humanCCND1 protein, humanCyclin D1DNA-Directed DNA PolymeraseDNA Polymerase thetaNeoplasm ProteinsCell biologyDNA repairHematologyLymphomas

Identifiers

PMID40608419
PMCPMC12404763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.